- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Rights Issue and Shortfall
Leap Therapeutics entered a clinical trial collaboration agreement with Merck to research a drug treatment combination for patients with relapsed or refractory advanced esophagogastric cancers.
Leap Therapeutics (NASDAQ:LPTX) entered a clinical trial collaboration agreement with Merck (NYSE:MRK) to research a drug treatment combination for patients with relapsed or refractory advanced esophagogastric cancers.
As quoted in the press release:
“This clinical collaboration with Merck is the first of the combination immunotherapy studies we plan to initiate in each of our two programs, DKN-01 and TRX518. Combining DKN-01 with KEYTRUDA has a strong scientific rationale and offers hope to patients with few treatment options,” commented Cynthia Sirard, M.D., Vice President, Clinical Development of Leap Therapeutics.
The study is expected to begin enrolling patients in the second-half of 2017. The collaboration agreement is between Leap and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
Click here to read the full press release.
Source: globenewswire.com
Outlook Reports
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2353.45 | -10.27 | |
Silver | 28.62 | +0.49 | |
Copper | 4.35 | +0.09 | |
Oil | 84.97 | -0.69 | |
Heating Oil | 2.65 | -0.03 | |
Natural Gas | 1.72 | -0.05 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.